<?xml version="1.0" encoding="UTF-8"?>
<p>aCRCS was developed using specimens only from unresectable or recurrent colorectal cancer to provide a novel classification method specific for mCRC. mCRCs are classified by aCRCS into 4 subtypes (A1, A2, B1, and B2). aCRCS has been reported to be a predictive factor for anti‚ÄêEGFR antibody therapy in 
 <italic>KRAS</italic> WT mCRC.
 <xref rid="cas14841-bib-0012" ref-type="ref">
  <sup>12</sup>
 </xref>
</p>
